Ryu Jae-Wook, Kim Youn Seup
Department of Thoracic and Cardiovascular Surgery, Dankook University College of Medicine, Cheonan, Korea.
Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea.
Tuberc Respir Dis (Seoul). 2015 Jan;78(1):36-40. doi: 10.4046/trd.2015.78.1.36. Epub 2015 Jan 29.
Malignant pleural mesothelioma (MPM) is an aggressive, treatment-resistant, and generally fatal disease. A 68-year-old male who was diagnosed with MPM at another hospital came to our hospital with dyspnea. We advised him to take combination chemotherapy but he refused to take the treatment. That was because he had already received chemotherapy with supportive care at another hospital but his condition worsened. Thus, we recommended photodynamic therapy (PDT) to deal with the dyspnea and MPM. After PDT, the dyspnea improved and the patient then decided to take the combination chemotherapy. Our patient received chemotherapy using pemetrexed/cisplatin. Afterwards, he received a single PDT treatment and then later took chemotherapy using gemcitabine/cisplatin. The patient showed a survival time of 27 months, which is longer than median survival time in advanced MPM patients. Further research and clinical trials are needed to demonstrate any synergistic effect between the combination chemotherapy and PDT.
恶性胸膜间皮瘤(MPM)是一种侵袭性强、对治疗耐药且通常致命的疾病。一名68岁男性在另一家医院被诊断为MPM,因呼吸困难前来我院。我们建议他进行联合化疗,但他拒绝接受治疗。这是因为他在另一家医院已经接受了化疗及支持治疗,但病情仍恶化。因此,我们推荐光动力疗法(PDT)来处理呼吸困难和MPM。PDT后,呼吸困难得到改善,患者随后决定接受联合化疗。我们的患者接受了培美曲塞/顺铂化疗。之后,他接受了单次PDT治疗,随后又接受了吉西他滨/顺铂化疗。该患者生存时间为27个月,长于晚期MPM患者的中位生存时间。需要进一步的研究和临床试验来证明联合化疗与PDT之间的任何协同作用。